A focused 2026 clinical landscape deep dive into NCT07691970, evaluating Anifrolumab-FNIA in Systemic Lupus Erythematosus: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07672561, evaluating WD-890 in Plaque Psoriasis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07617597, evaluating Deuruxolitinib Phosphate in Alopecia Areata: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07670546, evaluating Olokizumab in Polymyalgia Rheumatica: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07682506, evaluating Tofacitinib etocomil in Vitiligo: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07523581, evaluating Exaluren in Alport Syndrome: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07587021, evaluating YOLT-203 in Primary Hyperoxaluria: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07614477, evaluating Civorebrutinib in Focal Segmental Glomerulosclerosis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07499700, evaluating BAT-4406F in Focal Segmental Glomerulosclerosis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07675668, evaluating QG101-23-0 in Hypertrophic Cardiomyopathy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT06830629, evaluating MZE-829 in APOL1-Mediated Kidney Disease: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07211685, evaluating BAY-3401016 in Alport Syndrome: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.